Covid-19. U07.1 COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Eligible patients receive 760 mg / day (equivalent to two tablets) d-reGliss (Iran Darok) for five days. Patients will receive other routine Covid-19 treatments acc
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Covid-19 diagnosis based on PCR test Hospitalized in the intensive care unit and under mechanical ventilation
Exclusion criteria
Exclusion criteria: 1. Patients with high blood pressure (<90/140) Patients with congestive heart failure Patients with severe liver, kidney and thyroid disease Concomitant use of warfarin, SSRI, MAOI, diuretics, antiarrhythmic drugs Treatment with antiviral drugs one month before entering the study Allergy to licorice Pregnancy and lactation Dissatisfaction of the patient or his legal guardian Infected with Covid-19 for at least 20 days prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average time out of intensive care unit. Timepoint: After discharge. Method of measurement: Number of hospitalization days. | — |
Secondary
| Measure | Time frame |
|---|---|
| Speed of recovery of Covid-19 clinical signs. Timepoint: The first and fourteenth day. Method of measurement: Percentage of improvement in symptoms.;Duration of hospitalization in the intensive care unit. Timepoint: After discharge or death. Method of measurement: Number of days of hospitalization.;Duration of mechanical ventilation. Timepoint: During hospitalization. Method of measurement: Number of days under mechanical ventilation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSarah Mousavi
Esfahan University of Medical Sciences
Outcome results
None listed